Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.57 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379834 | 1.00 | GRIN1 (0.57) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL30275282 | 0.82 | L3MBTL1 (0.59) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL6847216 | 0.82 | L3MBTL1 (0.59) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL11309449 | 0.80 | GRIN2D (0.67) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL11309438 | 0.80 | GRIN2D (0.67) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL3697881 | 0.79 | GAA (0.44) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL534274 | 0.76 | GRIN2D (0.57) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL16256569 | 0.76 | GRIN2D (0.52) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL30862631 | 0.76 | GRIN2D (0.57) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A | |
| SCHEMBL20217222 | 0.76 | GRIN2D (0.52) | GRIN1GRIN2BGRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | INFLECTIS BIOSCIENCE (FR) | 2020-06-09 | — | — | US | disclosed |
| EP-3164391-B1 | O-ALKYL-BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF DISORDERS ASSOCIATED AN ACCUMULATION OF MISFOLDED PROTEINS | INFLECTIS BIOSCIENCE (FR) | 2019-07-31 | — | — | EP | disclosed |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | INFLECTIS BIOSCIENCE (FR) | 2018-08-09 | — | — | US | disclosed |
| WO-2017021216-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT. | INFLECTIS BIOSCIENCE (FR) | 2017-02-09 | — | — | WO | disclosed |
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2086973-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | Amgen Inc., (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008045393-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045393-A2 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | GRIN1 2348/4885GRIN2B 3086/4885GRIN2D 4011/4885 |
| US-20180221310-A1 | METHOD OF TREATING CANCER WITH A COMBINATION OF BENZYLIDENEGUANIDINE DERIVATIVES AND CHEMOTHERAPEUTIC AGENT | MGMT, GLI1, CA9 | GRIN1 1378/4885GRIN2B 973/4885GRIN2D 1186/4885 |
| US-10675257-B2 | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent | MGMT, GLI1, CA9 | GRIN1 1378/4885GRIN2B 973/4885GRIN2D 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.